Genenta Science S.p.A. (NASDAQ:GNTA - Get Free Report) was the recipient of a significant drop in short interest in May. As of May 31st, there was short interest totalling 2,000 shares, a drop of 31.0% from the May 15th total of 2,900 shares. Based on an average daily volume of 18,900 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the shares of the stock are sold short.
Institutional Investors Weigh In On Genenta Science
Several large investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC bought a new position in Genenta Science during the 4th quarter valued at about $46,000. Algebris UK Ltd grew its holdings in shares of Genenta Science by 122.2% in the first quarter. Algebris UK Ltd now owns 100,000 shares of the company's stock worth $368,000 after purchasing an additional 55,000 shares during the last quarter. Finally, Allianz SE purchased a new position in Genenta Science in the 4th quarter worth about $444,000. 15.13% of the stock is owned by institutional investors.
Genenta Science Stock Down 9.0%
Genenta Science stock opened at $3.53 on Tuesday. Genenta Science has a 52-week low of $2.79 and a 52-week high of $7.28. The firm's fifty day moving average is $4.12 and its 200 day moving average is $4.22.
Genenta Science Company Profile
(
Get Free Report)
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Genenta Science, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genenta Science wasn't on the list.
While Genenta Science currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
